Portland, OR, United States of America

Patricia Smith

This inventor holds 1 USPTO granted patent. Top assignee: Oregon Health & Science University. Active years: 2002.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Patricia Smith: Innovator in Cell Migration Research

Introduction

Patricia Smith is a notable inventor based in Portland, OR (US). She has made significant contributions to the field of medical research, particularly in the area of cell migration and its implications for various diseases.

Latest Patents

Patricia Smith holds a patent titled "Prevention of cell migration initiation with CMV US28 receptor antagonists." This patent describes an assay system for determining therapeutic activity for treating conditions such as restenosis, atherosclerosis, chronic rejection syndrome, and graft versus host disease (GVHD). The invention outlines methods for measuring the inhibition of cell migration in smooth muscle cells expressing a US28 receptor from the CMV genome. It also details a method for treating these conditions by administering an effective amount of a US28 receptor antagonist.

Career Highlights

Patricia Smith is affiliated with Oregon Health & Science University, where she conducts her research. Her work focuses on innovative approaches to understanding and treating complex medical conditions through the modulation of cell migration.

Collaborations

Patricia has collaborated with esteemed colleagues such as Cecilia E Soderberg-Naucler and Daniel Streblow, contributing to advancements in her field.

Conclusion

Patricia Smith's innovative research and patent contributions highlight her role as a leading inventor in the medical field. Her work continues to pave the way for new therapeutic strategies in treating serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…